Page last updated: 2024-08-26

arsenic and Myeloproliferative Disorders

arsenic has been researched along with Myeloproliferative Disorders in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (33.33)29.6817
2010's2 (66.67)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Foley, SB; Hildenbrand, ZL; Mgbemena, VE; Oravecz-Wilson, KI; Philips, ST; Ross, TS1
Canestraro, M; Cine, N; Galimberti, S; Guerrini, F; Metelli, MR; Nagy, B; Palumbo, GA; Petrini, M; Piaggi, S; Savli, H; Tibullo, D1
Caldas, C; Chin, SF; Cowell, JK; Kasyapa, CS; Kunapuli, P1

Other Studies

3 other study(ies) available for arsenic and Myeloproliferative Disorders

ArticleYear
Toward a therapeutic reduction of imatinib refractory myeloproliferative neoplasm-initiating cells.
    Oncogene, 2014, Nov-13, Volume: 33, Issue:46

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Benzamides; Blotting, Western; Bone Marrow Transplantation; Core Binding Factor Alpha 2 Subunit; Disease Models, Animal; DNA-Binding Proteins; Drug Resistance, Neoplasm; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cells; Humans; Imatinib Mesylate; Mice, Inbred C57BL; Mice, Transgenic; Myeloproliferative Disorders; Neoplasm Recurrence, Local; Neoplastic Stem Cells; Oligonucleotide Array Sequence Analysis; Oxides; Piperazines; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; Treatment Outcome

2014
Synergistic antiproliferative effect of arsenic trioxide combined with bortezomib in HL60 cell line and primary blasts from patients affected by myeloproliferative disorders.
    Cancer genetics and cytogenetics, 2010, Volume: 199, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; Biomarkers, Tumor; Blast Crisis; Blotting, Western; Boronic Acids; Bortezomib; Caspase 8; Cell Cycle; Cell Proliferation; Drug Synergism; Gene Expression Profiling; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Myeloproliferative Disorders; NF-kappa B; Oligonucleotide Array Sequence Analysis; Oxides; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Reactive Oxygen Species; Receptors, TNF-Related Apoptosis-Inducing Ligand; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; TNF-Related Apoptosis-Inducing Ligand

2010
ZNF198, a zinc finger protein rearranged in myeloproliferative disease, localizes to the PML nuclear bodies and interacts with SUMO-1 and PML.
    Experimental cell research, 2006, Nov-15, Volume: 312, Issue:19

    Topics: Amino Acid Substitution; Apoptosis; Arsenic Trioxide; Arsenicals; Binding Sites; Carrier Proteins; Cell Line; Cell Nucleus Structures; Dimerization; DNA-Binding Proteins; Gene Fusion; Gene Rearrangement; Humans; In Vitro Techniques; Mutagenesis, Site-Directed; Mutant Chimeric Proteins; Myeloproliferative Disorders; Neoplasm Proteins; Nuclear Proteins; Oxides; Plasminogen Activator Inhibitor 2; Promyelocytic Leukemia Protein; Receptor, Fibroblast Growth Factor, Type 1; SUMO-1 Protein; Transcription Factors; Tumor Suppressor Proteins; Two-Hybrid System Techniques; Zinc Fingers

2006